Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruplizumab

X
Drug Profile

Ruplizumab

Alternative Names: 5c8; 5c8 humanised monoclonal antibody; Anti-CD154 monoclonal antibody; Anti-CD40 ligand antibody; Anti-CD40 ligand monoclonal antibody; Anti-CD40 ligand monoclonal antibody 5c8; Anti-gp39 monoclonal antibody - Biogen; Antova; BG 9588; CD40 ligand monoclonal antibody - Biogen; hu5c8; Humanised CD40 ligand antibody/5c8; T cell-B cell activation molecule; T-BAM

Latest Information Update: 07 Mar 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Haemophilia A; Idiopathic thrombocytopenic purpura; Multiple sclerosis; Renal transplant rejection; Systemic lupus erythematosus

Most Recent Events

  • 28 Aug 2001 A study has been added to the adverse events and Transplant Rejection therapeutic trials sections
  • 22 Aug 2001 Anti-CD40 ligand monoclonal antibody 5c8 is now called Ruplizumab
  • 28 Apr 2000 A clinical study has been added to the therapeutic trials section of haematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top